The global transgenic animal model market is projected to grow to $6.79 billion by 2035, fueled by advances in CRISPR-Cas9 technology and rising demand for precise preclinical testing in drug development. Rodents dominate the market, with pharmaceutical and biotech companies as the main users, especially in oncology and personalized medicine. North America leads due to strong biopharma R&D and infrastructure. Despite challenges like high costs and ethical concerns, innovations in gene editing and AI integration promise continued market expansion and improved drug discovery outcomes.
Baker Hughes Company is set to report its Q2 2026 earnings with analysts forecasting EPS between $0.49 and $0.51 and revenue around $6.49 to $6.51 billion, both reflecting a year-over-year decline. Despite this, the company has a solid track record o...
Faraday Future Intelligent Electric Inc. saw its stock drop nearly 40% despite recent product showcases, indicating investor worries beyond its new offerings. Zevra Therapeutics' shares fell almost 24% after the European Medicines Agency issued a neg...
Stocks of several companies jumped significantly today due to key corporate developments. STAK Inc. led with a 596% rise after announcing a U.S. subsidiary to develop power systems for AI data centers, highlighting investor interest in AI infrastruct...
NovaBridge Biosciences announced its annual general meeting (AGM) will be held on September 8, 2026, in Shanghai. The company is advancing clinical-stage biopharmaceutical treatments, including givastomig for gastric cancer and VIS-101 for retinal di...
Pelthos Therapeutics announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026, at 9:00 a.m. Eastern Time. Stockholders of record as of August 4, 2026, are eligible to vote. The company will file the official noti...
